Segment Information (Schedule of Financial Data for Business Segments) (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended
	Sep. 30, 2013 segment	Sep. 30, 2012 Successor [Member]	Sep. 30, 2013 Successor [Member]	Sep. 30, 2013 Successor [Member]	Sep. 30, 2012 Successor [Member] Par Pharmaceutical [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member]	Sep. 30, 2013 Successor [Member] Par Pharmaceutical [Member]	Sep. 30, 2012 Successor [Member] Strativa [Member]	Sep. 30, 2013 Successor [Member] Strativa [Member]	Sep. 30, 2013 Successor [Member] Strativa [Member]	Sep. 28, 2012 Predecessor [Member]	Sep. 28, 2012 Predecessor [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member]	Sep. 28, 2012 Predecessor [Member] Strativa [Member]	Sep. 28, 2012 Predecessor [Member] Strativa [Member]
Segment Reporting Information [Line Items]
Number of business segments	2
Total revenues		$ 10,689	$ 267,321	$ 791,186	$ 10,689	$ 249,818	$ 737,733	$ 0	$ 17,503	$ 53,453	$ 238,063	$ 803,868	$ 218,614	$ 742,890	$ 19,449	$ 60,978
Total gross margin		3,627	81,391	211,735	3,627	69,506	175,502	0	11,885	36,233	101,350	342,350	86,611	296,184	14,739	46,166
Total operating (loss) income		3,339	(24,725)	(23,615)	3,339	(18,352)	(19,169)	0	(6,373)	(4,446)	(2,118)	59,440	11,023	116,466	(13,141)	(57,026)
Interest income		0	14	70							148	424
Interest expense		(824)	(23,385)	(71,033)							(2,996)	(9,159)
Loss on debt extinguishment		0	0	(7,335)							0	0
(Benefit) provision for income taxes		927	(18,797)	(36,077)							(3,588)	29,529
Net (loss) income		$ 1,588	$ (29,299)	$ (65,836)							$ (1,378)	$ 21,176